Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (191-200 of 250) with videos related to

Pageof 25
Sort By:
Cancer Research and Treatment|November 10, 2020
Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 PatientsJwa Hoon Kim, Jae Ho Jeong, Baek-Yeol Ryoo, et al.
Cancers|March 10, 2022
Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched AnalysisYoung Seob Shin, Hee Hyun Park, Jin-Hong Park, et al.
Cancers|March 1, 2019
Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective AnalysisChanghoon Yoo, Sang Hyun Shin, Kyu-Pyo Kim, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|February 23, 2024
Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinomaHyunseok Yoon, Yeokyeong Shin, Baek-Yeol Ryoo, et al.
Therapeutic Advances in Medical Oncology|May 16, 2022
Real-world outcomes of adjuvant gemcitabine <i>versus</i> gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinomaSora Kang, Changhoon Yoo, So Heun Lee, et al.
Cancer Research and Treatment|March 14, 2023
Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOXSo Heun Lee, Dae Wook Hwang, Changhoon Yoo, et al.
The International Journal of Biological Markers|June 8, 2018
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatinHeejung Chae, Hyungwoo Cho, Changhoon Yoo, et al.
Investigational New Drugs|April 5, 2018
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysisJihoon Kang, Inhwan Hwang, Changhoon Yoo, et al.
Therapeutic Advances in Medical Oncology|September 28, 2020
FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinomaChanghoon Yoo, Inhwan Hwang, Tae Jun Song, et al.
Investigational New Drugs|August 8, 2017
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testingKyoungmin Lee, Changhoon Yoo, Kyu-Pyo Kim, et al.
Pageof 25

Showing results (191-200 of 250) with videos related to

Sort By:
Pageof 25
Cancer Research and Treatment|November 10, 2020
Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 PatientsJwa Hoon Kim, Jae Ho Jeong, Baek-Yeol Ryoo, et al.
Cancers|March 10, 2022
Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched AnalysisYoung Seob Shin, Hee Hyun Park, Jin-Hong Park, et al.
Cancers|March 1, 2019
Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective AnalysisChanghoon Yoo, Sang Hyun Shin, Kyu-Pyo Kim, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|February 23, 2024
Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinomaHyunseok Yoon, Yeokyeong Shin, Baek-Yeol Ryoo, et al.
Therapeutic Advances in Medical Oncology|May 16, 2022
Real-world outcomes of adjuvant gemcitabine <i>versus</i> gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinomaSora Kang, Changhoon Yoo, So Heun Lee, et al.
Cancer Research and Treatment|March 14, 2023
Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOXSo Heun Lee, Dae Wook Hwang, Changhoon Yoo, et al.
The International Journal of Biological Markers|June 8, 2018
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatinHeejung Chae, Hyungwoo Cho, Changhoon Yoo, et al.
Investigational New Drugs|April 5, 2018
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysisJihoon Kang, Inhwan Hwang, Changhoon Yoo, et al.
Therapeutic Advances in Medical Oncology|September 28, 2020
FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinomaChanghoon Yoo, Inhwan Hwang, Tae Jun Song, et al.
Investigational New Drugs|August 8, 2017
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testingKyoungmin Lee, Changhoon Yoo, Kyu-Pyo Kim, et al.
Pageof 25